Assessment of a revolving drug fund for essential asthma medicines in Benin

被引：5
作者：
Agodokpessi G. [1 ]
Aït-Khaled N. [2 ]
Gninafon M. [1 ]
Tawo L. [1 ]
Bekou W. [1 ]
Perrin C. [2 ]
Bissell K. [2 ]
Billo N. [2 ]
Enarson D.A. [2 ]
Chiang C.-Y. [2 ,3 ,4 ]
机构：
[1] Centre National Hospitalier de Pneumo phtisiolologie, Cotonou
[2] International Union Against Tuberculosis and Lung Disease, 68,boulevard Saint-Michel, Paris
[3] Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei
[4] Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei
来源：
Journal of Pharmaceutical Policy and Practice | / 8卷 / 1期
关键词：
Asthma; Beclometasone; Inhaled corticosteroid; Revolving drug fund;
D O I：
10.1186/s40545-015-0033-7
中图分类号：
学科分类号：
摘要：
Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines. © 2015 Morrow; licensee BioMed Central.
引用
收藏
页码：1 / 8
页数：7
相关论文
共 20 条
  • [1] Hogerzeil H.V., Liberman J., Wirtz V.J., Kishore S.P., Selvaraj S., Kiddell-Monroe R., Et al., Promotion of access to essential medicines for non-communicable diseases: Practical implications of the UN political declaration, Lancet, 381, pp. 680-689, (2013)
  • [2] Cameron A., Ewen M., Ross-Degnan D., Ball D., Laing R., Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis, Lancet, 373, pp. 240-249, (2009)
  • [3] Babar Z.U., Lessing C., Mace C., Bissell K., The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries, Pharmacoeconomics, 31, pp. 1063-1082, (2013)
  • [4] Ait-Khaled N., Auregan G., Bencharif N., Mady Camara L., Dagli E., Djankine K., Et al., Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries, Int J Tuberc Lung Dis, 4, pp. 268-271, (2000)
  • [5] Ait-Khaled N., Enarson D.A., Bissell K., Billo N.E., Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries, Allergy, 62, pp. 230-236, (2007)
  • [6] Burney P., Potts J., Ait-Khaled N., Sepulveda R.M.D., Zidouni N., Benali R., Et al., A multinational study of treatment failures in asthma management, Int J Tuberc Lung Dis, 12, pp. 13-18, (2008)
  • [7] The Global Asthma Report 2011, (2011)
  • [8] Murakami H., Phommasack B., Oula R., Sinxomphou S., Revolving drug funds at front-line health facilities in Vientiane, Lao PDR, Health Policy Plan, 16, pp. 98-106, (2001)
  • [9] Umenai T., Narula I.S., Revolving drug funds in Asia and Latin America, Lancet, 347, pp. 1698-1699, (1996)
  • [10] Umenai T., Narula I.S., Revolving drug funds: A step towards health security, Bull World Health Organ, 77, pp. 167-171, (1999)
12